Patents by Inventor Philip R. Johnson, Jr.

Philip R. Johnson, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EXPRESSION OF VIRUS ENTRY INHIBITORS AND RECOMBINANT AAV THEREFOR
    Publication number: 20150044170
    Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.
    Type: Application
    Filed: April 9, 2014
    Publication date: February 12, 2015
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Philip R. Johnson, JR., Kelly Reed Clark
  • Recombinant adeno-associated virus production
    Patent number: 8409842
    Abstract: The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, the invention relates to use of recombinant adenovirus encoding adeno-associated virus protein in recombinant adeno-associated virus production methods.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: April 2, 2013
    Assignee: Nationwide Children's Hospital, Inc.
    Inventors: Kelly Reed Clark, Philip R. Johnson, Jr.
  • EXPRESSION OF VIRUS ENTRY INHIBITORS AND RECOMBINANT AAV THEREFOR
    Publication number: 20120171160
    Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.
    Type: Application
    Filed: February 6, 2012
    Publication date: July 5, 2012
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Philip R. Johnson, JR., Kelly Reed Clark
  • ANTIBODY GENE TRANSFER AND RECOMBINANT AAV THEREFOR
    Publication number: 20120027798
    Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.
    Type: Application
    Filed: July 6, 2011
    Publication date: February 2, 2012
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: Kelly Reed Clark, Philip R. Johnson, JR.
  • Production of rAAV in Vero Cells Using Particular Adenovirus Helpers
    Publication number: 20110201088
    Abstract: The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, in some embodiments the invention contemplates the use of an adenovirus known as Simian Adenovirus 13 (SAdV-13) and Vero cells for production of recombinant adeno-associated virus (rAAV).
    Type: Application
    Filed: April 6, 2011
    Publication date: August 18, 2011
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL INC.
    Inventors: Clifford J. Beall, Kelly R. Clark, Philip R. Johnson, JR.
  • Production of rAAV in vero cells using particular adenovirus helpers
    Patent number: 7943379
    Abstract: The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, in some embodiments the invention contemplates the use of an adenovirus known as Simian Adenovirus 13 (SAdV-13) and Vero cells for production of recombinant adeno-associated virus (rAAV).
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: May 17, 2011
    Assignee: Nationwide Children's Hospital, Inc.
    Inventors: Clifford J. Beall, Kelly R. Clark, Philip R. Johnson, Jr.
  • Adeno-associated virus materials and methods
    Patent number: 7662627
    Abstract: The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: February 16, 2010
    Assignee: Nationwide Children's Hospital, Inc.
    Inventor: Philip R. Johnson, Jr.
  • PRODUCTION OF rAAV IN VERO CELLS USING PARTICULAR ADENOVIRUS HELPERS
    Publication number: 20090275138
    Abstract: The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, in some embodiments the invention contemplates the use of an adenovirus known as Simian Adenovirus 13 (SAdV-13) and Vero cells for production of recombinant adeno-associated virus (rAAV).
    Type: Application
    Filed: April 30, 2009
    Publication date: November 5, 2009
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL
    Inventors: Clifford J. Beall, Kelly R. Clark, Philip R. Johnson, JR.
  • Expression of virus entry inhibitors and recombinant AAV therefor
    Publication number: 20090169513
    Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.
    Type: Application
    Filed: March 24, 2008
    Publication date: July 2, 2009
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL
    Inventors: Philip R. Johnson, JR., Kelly Reed Clark
  • Antibody Gene Transfer and Recombinant AAV Therefor
    Publication number: 20090035327
    Abstract: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.
    Type: Application
    Filed: June 25, 2008
    Publication date: February 5, 2009
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL
    Inventors: Kelly Reed Clark, Philip R. Johnson, JR.
  • Adeno-associated virus materials and methods
    Patent number: 7070998
    Abstract: The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: July 4, 2006
    Assignee: Children's Hospital, Inc.
    Inventor: Philip R. Johnson, Jr.